STAT

Documentarian Alex Gibney has taken on Enron, Scientology — and now Theranos

Documentarian Alex Gibney's latest subject — after Enron executives, cyclist Lance Armstrong, and a Scientology leader — is Elizabeth Holmes of Theranos.
Source: Kristoffer Tripplaar/AP

For more news about West Coast life sciences, health care, and biotech, sign up to receive “Go West,” STAT’s weekly newsletter.

SAN FRANCISCO — In Alex Gibney’s career as a documentarian, he’s spent a lot of time peering into ingenious fraudsters, liars, and questionable charismatic figures. Among them: the Enron executives, the cyclist Lance Armstrong, and Scientology leader David Miscavige.

Which is why it comes as no surprise that his latest subject is Elizabeth Holmes.

Gibney’s Theranos documentary, “The Inventor,” will be in theaters for one week starting on Friday in San Francisco, Los Angeles, and New York City. It will premiere on HBO on Monday night. STAT sat down with Gibney to talk about his new film at a premiere on Monday night here in the lion’s den.

In your view, how does Elizabeth Holmes compare to some of these other figures you’ve made films about? In what ways does she stand out — and where do you

Stai leggendo un'anteprima, registrati per continuare a leggere.

Altro da STAT

STAT4 min lettiSociety
Doctors Argue For Term Limits To Diversify Medical School Leadership
In a new paper, a group of doctors argues that medical schools should impose term limits on department chairs and deans to bring in more diverse perspectives.
STAT4 min lettiLeadership & Mentoring
Opinion: New Leaders Needed To Translate Discoveries Into Patient Care
To facilitate new discoveries, today's and tomorrow's leaders need to understand and navigate the languages and cultures of multiple sectors, from health care systems and academia to industry, finance, and…
STAT2 min lettiScience
New Vertex Cystic Fibrosis Drug Approved, Extending Treatments To 90% Of Patients
Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of therapy to 90% of CF patients. The drug will be marketed as Trikafta. The list price is $311,000 per year — the